We are delighted to announce that Molten Ventures has led a £11.5 million Series A funding round in IMU Biosciences, a techbio company revolutionising immune powered precision medicine.
IMU.
IMU Biosciences secures £11 5 million in Series A funding to revolutionise immune powered precision medicine tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Abingworth, a leading international life sciences investor, announces its portfolio company Adaptate Biotherapeutics ("Adaptate") is to be.
Second Abingworth gamma delta T cell company, Adaptate Biotherapeutics, to be acquired by Takeda streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.